Developer docs
API playgroundTry for free, no card

Search company profiles

Exeltis

Full company profile

uuid02lzh8h

Namestring
Exeltis
Legal namestring
Exeltis S.A.S.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Exeltis S.A.S. is the Colombian subsidiary of Spanish multinational Insud Pharma, founded in Colombia in 2016 and headquartered in Bogotá. The company develops, markets, and distributes a portfolio of pharmaceutical products, dietary supplements, and medical devices focused exclusively on women's health across life stages — contraception (oral contraceptives and vaginal rings such as Slinda), pregnancy support (Bonjesta for nausea/vomiting, SMPS prenatal supplements), HPV and cervical health (Deflagyn medical device), endometriosis, menopause (Exelfem), and nutritional supplementation (ExelMyo, Exelageno, ExelGes-B). Its product offering is backed by 300+ SKUs and benefits from Insud Pharma group's 15 industrial plants, 10 R&D centers, and operations in 40+ countries.

The company operates a hybrid go-to-market model: prescription pharmaceuticals are driven through healthcare professional engagement targeting gynecologists, obstetricians, and general practitioners — supported by a credentialed Exeltis Medical Experience portal validated against Ministry of Health databases — while OTC dietary supplements and select products are sold directly through seven major Colombian pharmacy chains (Farmatodo, La Rebaja, Colsubsidio, Cruz Verde, Pasteur, Lopido, CAFAM) across both physical and online channels. By 2020, Exeltis reached #2 share in Colombia's prescription oral contraceptive market (advancing from #4 in 2019), and by 2022 had distributed 915,000 cumulative treatments to Colombian women. Patient education tools including the PUQE-24 nausea severity assessment, menopause quizzes, and disease-state content across HPV, endometriosis, and nutrients round out a content-marketing layer aimed at both consumers and HCPs.

Revenue is generated through one-time product sales across prescription and supplement lines, with no subscription, licensing, or platform recurring component. The Colombian entity operates as a wholly-owned subsidiary under the Insud Pharma group, with no disclosed external investors, debt, or equity funding events; the local team is lean (1–10 listed employees) and relies on group-level R&D, manufacturing, and brand infrastructure for product supply. Exeltis is led by Country Manager Adriana Cleves, and the company maintains active consumer-facing social media channels (Instagram, Facebook) alongside HCP-facing digital engagement.

Short descriptiontext

Exeltis S.A.S., the Colombian subsidiary of Spain's Insud Pharma, develops and distributes pharmaceutical products, dietary supplements, and medical devices exclusively for women's health across pregnancy, contraception, HPV, endometriosis, menopause, and nutrition, selling through major pharmacy chains and healthcare professionals in Colombia since 2016.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSuba, Colombia
HQ citystring
Suba
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health pharmaceuticals, oral contraceptives, prenatal supplements, menopausal therapy, HPV medical devices
Industry4 codes
1Women’s Health & Reproductive Specialty Pharmaceuticals
CodeHLAIACANPrimaryYes
2Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
CodeHLAIAAAJPrimaryNo
3Women’s Health Supplements (Prenatal, Menopause, Hormonal)
CodeCRADAGAKPrimaryNo
4Menstrual Pain Relief & Period Care Supplements
CodeCRABAIAJPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Products - Women's Health
TypeOne Time License
Description

Exeltis generates revenue through the sale of prescription and OTC pharmaceutical products focused on women's health including oral contraceptives, pregnancy supplements, endometriosis treatments, HPV management, and menopausal therapies. The company offers over 300 products for health and wellness.

exeltiscolombia.com
2Dietary Supplements
TypeOne Time License
Description

Sale of dietary supplements including Myo-Inositol formulations, iron supplements, complex B vitamins, collagen with biotin, vitamin D, and other micronutrients targeting women's health across life stages.

exeltiscolombia.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Prescription pharmaceuticals and OTC dietary supplements sold through retail pharmacy partners
ModelOtherBilling cadencePay-as-you-go
Notes

Products distributed through pharmacy chains including Farmatodo, La Rebaja, Colsubsidio, Cruz Verde, Pasteur, Lopido, and CAFAM. Specific pricing not disclosed on website; consumers purchase through retail pharmacies with or without prescription depending on product category.

exeltiscolombia.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ExelMyo
Description

Dietary supplement product for women's health

exeltiscolombia.com
+4 more records
Core offering1 text field

Exeltis develops, manufactures, and markets prescription pharmaceuticals and over-the-counter dietary supplements focused exclusively on women's health, spanning pregnancy support, oral and vaginal contraception, HPV management, endometriosis, menopause, and nutritional supplementation. The Colombian operation sells a portfolio of more than 300 products through national pharmacy chains and via healthcare professional prescriptions, supported by an HCP-exclusive medical information portal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Exeltis distributed 915,000 treatments to women in Colombia by 2022
+3 more records
Product overview1 text field

Exeltis is a multinational pharmaceutical company specializing in women's health, offering a portfolio of pharmaceutical products, dietary supplements, and medical devices. The product portfolio includes contraceptives (Slinda), pregnancy support products (Bonjesta), dietary supplements (ExelMyo, Exelageno, Exelfem, ExelGes-B), HPV-related medical devices (Deflagyn), and a healthcare professional portal (Exeltis Medical Experience). The company operates primarily in women's health across key life stages including pregnancy, contraception, and menopause, with operations in Colombia since 2016.

Product and service7 records
1Bonjesta
CategoryPharmaceutical product
Description

Prescription pharmaceutical for managing nausea and vomiting during pregnancy (NVP), targeting pregnant women in Colombia.

2Slinda
CategoryContraceptive
Description

Oral contraceptive for family planning, prescribed to women in Colombia through gynecologists and pharmacists.

3Deflagyn
CategoryMedical device
Description

Medical device for HPV (Human Papillomavirus) support and care, targeted at Colombian women requiring HPV coadjuvant management.

4ExelMyo
CategoryDietary supplement
Description

Dietary supplement containing Myo-Inositol for hormonal balance and insulin sensitivity, marketed to women for PCOS and general women's wellness in Colombia.

5Exelageno
CategoryDietary supplement
Description

Dietary supplement for women's health and wellness, distributed through Colombian pharmacy chains.

6Exelfem
CategoryDietary supplement
Description

Dietary supplement supporting women's health across life stages, including menopause, distributed through Colombian pharmacies.

7ExelGes-B
CategoryDietary supplement
Description

Dietary supplement supporting women's nutritional health, sold through Colombian pharmacy retail.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Major Colombian pharmacy chain serving as primary retail distribution channel for Exeltis dietary supplements and select products. Products available through both physical store locations and online ordering platform.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Major Colombian pharmacy chain with extensive retail presence used for Exeltis product distribution across Colombia.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Colsubsidio pharmacy chain affiliated with Colombian social security system serving as distribution partner for Exeltis products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

National pharmacy chain with both retail and e-commerce presence distributing Exeltis products in Colombia.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional pharmacy chain in Colombia serving as distribution channel for Exeltis products.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Online pharmacy platform enabling digital distribution of Exeltis products to consumers.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

CAFAM pharmacy and wellness stores affiliated with Colombian teachers' pension fund serving as distribution channel.

Strategic tierCoreTypeOthers
Description

Exeltis is a subsidiary of Insud Pharma, a Spanish multinational pharmaceutical group. Exeltis was created through the evolution and sustained growth of Insud Pharma, benefiting from 40 years of experience, 15 manufacturing plants, 10 R&D centers, and presence in 40+ countries.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spun off from Merck to focus on women's health, biosimilars, and established brands - operates a portfolio that overlaps head-to-head with Exeltis in contraception, fertility, and women's health across global and Latin American markets.

TypeRegional player
Description

Latin American (Brazilian) pharmaceutical multinational with a broad women's health and supplement portfolio; competes with Exeltis in the regional Latin American market but with a different home-country footprint.

TypeDirect peer
Description

Specialty women's health pharmaceutical company (now part of Perrigo) focusing on reproductive health, emergency contraception, and gynecological therapies - mirrors Exeltis's specialty-pharma model and category focus.

TypeEmerging player
Description

U.S.-focused women's health specialty pharma (menopause, reproductive health) - comparable scale and therapeutic focus but geographically concentrated in North America rather than Latin America.

TypeRegional player
Description

Mexican-based Latin American pharmaceutical and consumer health company with women's health and supplement brands competing in retail pharmacy channels across the region, including Colombia.

TypeDirect peer
Description

Women's health specialty pharmaceutical company offering contraception, menopause, and reproductive health products globally; most directly comparable to Exeltis given similar women's-health-only focus and reliance on HCP engagement.

TypeBroad incumbent
Description

Diversified healthcare incumbent with established women's health, prenatal nutrition, and contraceptive products marketed in Colombia; broader portfolio incumbent with significant share in prenatal supplements where Exeltis also competes.

TypeDirect peer
Description

European specialty pharmaceutical company with a dedicated women's health franchise (contraception, menopause, fertility); competes with Exeltis in similar therapeutic categories and has footprint across multiple Latin American countries.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with a major women's health franchise (oral contraceptives like Yaz/Yasmin, IUDs, menopause); competes broadly with Exeltis in Colombia's contraceptive market from a much larger commercial and R&D base.

TypeBroad incumbent
Description

Multinational incumbent with established women's health products and large-scale Colombian operations - represents deep-pocketed competition in both prescription women's health and consumer supplements via its portfolio breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exeltis

Women's Health Pharmaceuticalsexeltiscolombia.com

Exeltis S.A.S., the Colombian subsidiary of Spain's Insud Pharma, develops and distributes pharmaceutical products, dietary supplements, and medical devices exclusively for women's health across pregnancy, contraception, HPV, endometriosis, menopause, and nutrition, selling through major pharmacy chains and healthcare professionals in Colombia since 2016.

What Exeltis does

Exeltis S.A.S. is the Colombian subsidiary of Spanish multinational Insud Pharma, founded in Colombia in 2016 and headquartered in Bogotá. The company develops, markets, and distributes a portfolio of pharmaceutical products, dietary supplements, and medical devices focused exclusively on women's health across life stages — contraception (oral contraceptives and vaginal rings such as Slinda), pregnancy support (Bonjesta for nausea/vomiting, SMPS prenatal supplements), HPV and cervical health (Deflagyn medical device), endometriosis, menopause (Exelfem), and nutritional supplementation (ExelMyo, Exelageno, ExelGes-B). Its product offering is backed by 300+ SKUs and benefits from Insud Pharma group's 15 industrial plants, 10 R&D centers, and operations in 40+ countries.

The company operates a hybrid go-to-market model: prescription pharmaceuticals are driven through healthcare professional engagement targeting gynecologists, obstetricians, and general practitioners — supported by a credentialed Exeltis Medical Experience portal validated against Ministry of Health databases — while OTC dietary supplements and select products are sold directly through seven major Colombian pharmacy chains (Farmatodo, La Rebaja, Colsubsidio, Cruz Verde, Pasteur, Lopido, CAFAM) across both physical and online channels. By 2020, Exeltis reached #2 share in Colombia's prescription oral contraceptive market (advancing from #4 in 2019), and by 2022 had distributed 915,000 cumulative treatments to Colombian women. Patient education tools including the PUQE-24 nausea severity assessment, menopause quizzes, and disease-state content across HPV, endometriosis, and nutrients round out a content-marketing layer aimed at both consumers and HCPs.

Revenue is generated through one-time product sales across prescription and supplement lines, with no subscription, licensing, or platform recurring component. The Colombian entity operates as a wholly-owned subsidiary under the Insud Pharma group, with no disclosed external investors, debt, or equity funding events; the local team is lean (1–10 listed employees) and relies on group-level R&D, manufacturing, and brand infrastructure for product supply. Exeltis is led by Country Manager Adriana Cleves, and the company maintains active consumer-facing social media channels (Instagram, Facebook) alongside HCP-facing digital engagement.

Exeltis firmographics

Firmographics
Name
Exeltis
Legal name
Exeltis S.A.S.
Website
https://exeltiscolombia.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Exeltis S.A.S., the Colombian subsidiary of Spain's Insud Pharma, develops and distributes pharmaceutical products, dietary supplements, and medical devices exclusively for women's health across pregnancy, contraception, HPV, endometriosis, menopause, and nutrition, selling through major pharmacy chains and healthcare professionals in Colombia since 2016.
Ownership category
akta.pro rank

Exeltis industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
akta.pro secondary industries
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK), Menstrual Pain Relief & Period Care Supplements (CRABAIAJ)

Keywords

  • Women's health pharmaceuticals
  • Oral contraceptives
  • Prenatal supplements
  • Menopausal therapy
  • HPV medical devices

Where Exeltis is headquartered

Location

Headquarters

HQ city
Suba
HQ country
Colombia
HQ region
Latin America

Offices2 records

Markets served

Exeltis business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Pharmaceutical Products - Women's Health: Exeltis generates revenue through the sale of prescription and OTC pharmaceutical products focused on women's health including oral contraceptives, pregnancy supplements, endometriosis treatments, HPV management, and menopausal therapies. The company offers over 300 products for health and wellness.
  2. Dietary Supplements: Sale of dietary supplements including Myo-Inositol formulations, iron supplements, complex B vitamins, collagen with biotin, vitamin D, and other micronutrients targeting women's health across life stages.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceuticals and OTC dietary supplements sold through retail pharmacy partners

Go-to-market motion2 records

Distribution channels8 records

Marketing channels7 records

Exeltis product offering

Product offering

Core offering

Exeltis develops, manufactures, and markets prescription pharmaceuticals and over-the-counter dietary supplements focused exclusively on women's health, spanning pregnancy support, oral and vaginal contraception, HPV management, endometriosis, menopause, and nutritional supplementation. The Colombian operation sells a portfolio of more than 300 products through national pharmacy chains and via healthcare professional prescriptions, supported by an HCP-exclusive medical information portal.

Product overview

Exeltis is a multinational pharmaceutical company specializing in women's health, offering a portfolio of pharmaceutical products, dietary supplements, and medical devices. The product portfolio includes contraceptives (Slinda), pregnancy support products (Bonjesta), dietary supplements (ExelMyo, Exelageno, Exelfem, ExelGes-B), HPV-related medical devices (Deflagyn), and a healthcare professional portal (Exeltis Medical Experience). The company operates primarily in women's health across key life stages including pregnancy, contraception, and menopause, with operations in Colombia since 2016.

Differentiator

Problem solved

Functional benefit

Brands

  • ExelMyo: Dietary supplement product for women's health
  • Exelageno
  • Exelfem
  • ExelGes
  • Bonjesta

Products and services

  • Bonjesta Prescription pharmaceutical for managing nausea and vomiting during pregnancy (NVP), targeting pregnant women in Colombia.
  • Slinda Oral contraceptive for family planning, prescribed to women in Colombia through gynecologists and pharmacists.
  • Deflagyn Medical device for HPV (Human Papillomavirus) support and care, targeted at Colombian women requiring HPV coadjuvant management.
  • ExelMyo Dietary supplement containing Myo-Inositol for hormonal balance and insulin sensitivity, marketed to women for PCOS and general women's wellness in Colombia.
  • Exelageno Dietary supplement for women's health and wellness, distributed through Colombian pharmacy chains.
  • Exelfem Dietary supplement supporting women's health across life stages, including menopause, distributed through Colombian pharmacies.
  • ExelGes-B Dietary supplement supporting women's nutritional health, sold through Colombian pharmacy retail.

Quantifiable outcome

  • Exeltis distributed 915,000 treatments to women in Colombia by 2022
  • +3 more outcomes

Companies that use Exeltis

Customer profile

Named customers4 records

Segments8 records

Ideal customer profiles4 records

Exeltis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Exeltis partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • FarmatodocoreChannel Partner/ Reseller/ DistributorMajor Colombian pharmacy chain serving as primary retail distribution channel for Exeltis dietary supplements and select products. Products available through both physical store locations and online ordering platform.
  • La RebajacoreChannel Partner/ Reseller/ DistributorMajor Colombian pharmacy chain with extensive retail presence used for Exeltis product distribution across Colombia.
  • ColsubsidiocoreChannel Partner/ Reseller/ DistributorColsubsidio pharmacy chain affiliated with Colombian social security system serving as distribution partner for Exeltis products.
  • Cruz VerdecoreChannel Partner/ Reseller/ DistributorNational pharmacy chain with both retail and e-commerce presence distributing Exeltis products in Colombia.
  • Farmacias PasteurminorChannel Partner/ Reseller/ DistributorRegional pharmacy chain in Colombia serving as distribution channel for Exeltis products.
  • LopidominorChannel Partner/ Reseller/ DistributorOnline pharmacy platform enabling digital distribution of Exeltis products to consumers.
  • CAFAMminorChannel Partner/ Reseller/ DistributorCAFAM pharmacy and wellness stores affiliated with Colombian teachers' pension fund serving as distribution channel.
  • Insud Pharma (Parent Company)coreOthersExeltis is a subsidiary of Insud Pharma, a Spanish multinational pharmaceutical group. Exeltis was created through the evolution and sustained growth of Insud Pharma, benefiting from 40 years of experience, 15 manufacturing plants, 10 R&D centers, and presence in 40+ countries.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Exeltis competitors and assessment

Company assessment

Direct peers

  • Organon: Spun off from Merck to focus on women's health, biosimilars, and established brands - operates a portfolio that overlaps head-to-head with Exeltis in contraception, fertility, and women's health across global and Latin American markets.
  • HRA Pharma: Specialty women's health pharmaceutical company (now part of Perrigo) focusing on reproductive health, emergency contraception, and gynecological therapies - mirrors Exeltis's specialty-pharma model and category focus.
  • Theramex: Women's health specialty pharmaceutical company offering contraception, menopause, and reproductive health products globally; most directly comparable to Exeltis given similar women's-health-only focus and reliance on HCP engagement.
  • Gedeon Richter: European specialty pharmaceutical company with a dedicated women's health franchise (contraception, menopause, fertility); competes with Exeltis in similar therapeutic categories and has footprint across multiple Latin American countries.

Regional players

  • Eurofarma: Latin American (Brazilian) pharmaceutical multinational with a broad women's health and supplement portfolio; competes with Exeltis in the regional Latin American market but with a different home-country footprint.
  • Genomma Lab: Mexican-based Latin American pharmaceutical and consumer health company with women's health and supplement brands competing in retail pharmacy channels across the region, including Colombia.

Emerging players

  • TherapeuticsMD: U.S.-focused women's health specialty pharma (menopause, reproductive health) - comparable scale and therapeutic focus but geographically concentrated in North America rather than Latin America.

Broad incumbents

  • Abbott (Pharmaceuticals): Diversified healthcare incumbent with established women's health, prenatal nutrition, and contraceptive products marketed in Colombia; broader portfolio incumbent with significant share in prenatal supplements where Exeltis also competes.
  • Bayer (Pharmaceuticals): Global pharmaceutical incumbent with a major women's health franchise (oral contraceptives like Yaz/Yasmin, IUDs, menopause); competes broadly with Exeltis in Colombia's contraceptive market from a much larger commercial and R&D base.
  • Pfizer: Multinational incumbent with established women's health products and large-scale Colombian operations - represents deep-pocketed competition in both prescription women's health and consumer supplements via its portfolio breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Exeltis social profiles

Digital presence

Exeltis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exeltis leadership team

Management profile

Number of profiles

Profiles1 record

Exeltis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exeltis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exeltis

What does Exeltis do?

Exeltis develops, manufactures, and markets prescription pharmaceuticals and over-the-counter dietary supplements focused exclusively on women's health, spanning pregnancy support, oral and vaginal contraception, HPV management, endometriosis, menopause, and nutritional supplementation. The Colombian operation sells a portfolio of more than 300 products through national pharmacy chains and via healthcare professional prescriptions, supported by an HCP-exclusive medical information portal.

Is Exeltis a public or private company?

Exeltis is a private company. It is classified as corporate owned and is currently operating.

When was Exeltis founded?

Exeltis was founded in 2016. It employs 1 to 10 people.

Where is Exeltis based?

Exeltis is headquartered in Suba, Colombia, in the Latin America region.

How does Exeltis make money?

Two revenue lines are on record. Pharmaceutical Products - Women's Health is the primary driver. The others are dietary Supplements.

Who are Exeltis's main competitors?

Direct peers on record are Organon, HRA Pharma, Theramex and Gedeon Richter. Regional players are Eurofarma and Genomma Lab. TherapeuticsMD is listed as an emerging player. Broad incumbents are Abbott (Pharmaceuticals), Bayer (Pharmaceuticals) and Pfizer.

Does Exeltis have an API?

No public API is recorded for Exeltis.

What industry is Exeltis in?

Exeltis's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales